Bruker Corporation ($BRKR) reports a 7.6% pre-market decline after releasing its First Quarter 2024 Financial Results. XPEL Inc. ($XPEL) experiences an 18% pre-market drop following the announcement of its First Quarter Results, which included a double miss and a reduction in FY 24 revenue growth projections. The CEO acknowledges challenges in Q1, particularly in the US aftermarket. Following the disappointing results, several analysts and investors express concerns and downgrade XPEL's stock, with B.Riley slashing the price target by 50% to $37. The stock continues to decline, with one tweet mentioning a 31% drop on Q1 results and nearly 60% decrease from last year's highs. Despite the downturn, some investors still see potential in XPEL, with one user highlighting the significant return since 2018. The stock faces further decline due to COVID-19 impacts, dropping another 50% to $15 and almost reaching sub $30 levels.